Skip to main content

DNAPrint Acquires Kenna Technologies in All-Stock Deal

NEW YORK, Nov. 1 (GenomeWeb News) - DNAPrint Genomics acquired privately held Kenna Technologies in an all-stock transaction, DNAPrint said today.

 

Shareholders of the West Chester, PA-based company exchanged all of their outstanding shares for 1.5 million shares of DNAPrint's common stock. The transaction took effect Oct. 25.

 

With the acquisition, DNAPRint gains Kenna's BoneFusion and CellCycleFusion models. BoneFusion simulates processes in bone remodeling and CellCycleFusion simulates molecular pathways that control basic cellular functions.

 

This is DNAPrint's second major acquisition for the year. The company acquired Trace Genetics in June and 18% of Biofrontera in July.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.